ASCO has finally launched the new membership model, which provides full access to educational resources, career development plans, multiple journals and discounted access to the Annual Meeting to the members. Join ASCO today! asco.org

ONO Pharmaceutical acquired Deciphera Pharmaceutical, Inc. Thanks to Deciphera for developing essential drugs for treatment or rare, important diseases such as GIST and tenosynovial giant cell tumor and thanks for the close interaction with the sarcoma community over the years

Op 1-8-2024 wordt prof. Paul Herijgers de nieuwe gedelegeerd bestuurder van UZ Leuven. Huidig CEO prof. Wim Robberecht: "Paul Herijgers kan bogen op zijn ervaring als vermaard chirurg in ons ziekenhuis en als gedreven decaan van de faculteit geneeskunde." bit.ly/3UdV1wQ

The sheer number and rapid increase in the number of (often duplicative) mandatory online training modules for clinical care, research, and institutional employment is completely unsustainable ⁦AMA⁩ ama-assn.org/practice-manag…

Yesterday I defended my doctoral thesis on the biology and drug sensitivity of selected mesenchymal malignancies. I am very grateful Patrick Schöffski, Aga Wozniak and Daphne Hompes for these past four years and I am looking forward to the next adventures on my path…

IDRX-42: next generation KIT inhibitor for treatment of gastrointestinal stromal tumor. Convincing safety profile and strong efficacy signal during Phase 1 dose escalation and recruitment ongoing in Phase 1b. Send your patients (all lines) to active sites! See ASCO 2024 #11501

The IDRX-42 GIST story: yet another example of reverse translation of our in vivo work with patient-derived mouse xenografts in the Lab of Experimental Oncology at KU Leuven providing a rationale for a clinical application. See De Sutter et al DOI: 10.1158/1078-0432.CCR-22-3822

After travelling to Chicago for scientific meetings at least 20 times I finally discovered by chance my own roots on Lincoln Ave…unglaublich!

👇🏼 Every word is true. Come take care of sarcoma patients with us.

The term "group leader" feels increasingly uncomfortable. It emphasizes a superstar individual, undervalues the team's role, and fails to convey the responsibility for the team's well-being. #Leadership #Teamwork Any alternatives?

Sarcomas are tumours of the bones, cartilage & connective tissues. Childrens Cancer Institute 's research team have established several new cell lines & identified a promising drug candidate which appears able to kill osteosarcoma cells without harming normal cells. #SarcomaAwarenessMonth

Are you developing or testing drugs for treatment of synovial sarcoma? This is the molecular epidemiology and prognostic impact of relevant targets such as MAGE-A4, NY-ESO-1, YAP-1, BRD9 and CXCR4: Read De Cock et al. Translational Oncology 2024, doi.org/10.1016/j.tran…

🚨Our latest paper evaluating #proteomic signatures with the Sarculator nomogram to predict high-risk #sarcoma patients is out in CancerMedicine! This is a wonderful collaboration with Sandro Pasquali Rosalba Miceli Alessandro Gronchi Istituto Tumori Read more here dx.doi.org/10.1002/cam4.7…

We are looking for a talented clinical investigator focused on urothelial cancer. Join a great team focused on eradicating GU cancers! externaltalent-mskcc.icims.com/jobs/72285/fac…

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

3 additional years of adjuvant imatinib reduces risk of relapse in GIST patients who have received 3 years of the drug. Congratulations to Blay et al! Which company will now apply for longer reimbursement in the era of cheap, generic imatinib? doi: 10.1016/j.annonc.2024.08.2343